Literature DB >> 26255191

The amount of citrullinated proteins in synovial tissue is related to serum anti-cyclic citrullinated peptide (anti-CCP) antibody levels.

Elizabeth Olivares-Martínez1, Diego F Hernández-Ramírez1, Carlos A Núñez-Álvarez1, Antonio R Cabral1, Luis Llorente2.   

Abstract

The objective of this study was to determine the relationship between citrullinated proteins in synovial tissue with peripheral anti-citrullinated peptides autoantibodies (ACPA) and peptidylarginine deiminase (PADI) PADI2, PADI3, and PADI4 messenger RNA (mRNA) expressions in synovial tissue and fibroblast-like synoviocytes in rheumatoid arthritis (RA) patients. Eleven RA and 12 osteoarthritis (OA) patients who underwent knee replacement surgery were studied. We detected citrullinated proteins in synovial tissue homogenates by western blot and serum ACPA by ELISA to anti-cyclic citrullinated peptide (anti-CCP) antibodies, and PADI2, PADI3, and PADI4 mRNA expressions in synovial tissue and in fibroblast-like synoviocytes. Patients with high amount of citrullinated proteins in synovial tissue (3 out of 7) have high levels of anti-CCP in serum. However, in the remaining 4 patients, the amount of synovial citrullinated proteins was minimal and their sera showed low levels of anti-CCP antibodies. Furthermore, we observed an increase in PADI2 mRNA expression in RA synovial tissue compared with OA patients (p = 0.02). We detected PADI3 mRNA in the synovial tissue of RA patients, but not in the tissue of OA patients. Even though fibroblast-type synoviocytes in RA are not the main source of PADs in the synovial tissue, they express PADI2 mRNA moderately, PADI4 mRNA weakly, while there is no detectable expression of PADI3 mRNA. In conclusion, we found a variety of citrullinated proteins in the synovial tissue of RA patients and the amount of such proteins is related to serum concentration of anti-CCP antibodies. We identified the presence of PADI3 mRNA expression in synovial tissue and PADI2 and PADI4 mRNA expressions in fibroblast-like synoviocytes from patients with RA.

Entities:  

Keywords:  Anti-citrullinated protein antibodies; Citrullinated proteins; Peptidyl arginine deiminase; Rheumatoid arthritis

Mesh:

Substances:

Year:  2015        PMID: 26255191     DOI: 10.1007/s10067-015-3047-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  35 in total

1.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

Authors:  G A Schellekens; H Visser; B A de Jong; F H van den Hoogen; J M Hazes; F C Breedveld; W J van Venrooij
Journal:  Arthritis Rheum       Date:  2000-01

2.  Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis.

Authors:  Akari Suzuki; Ryo Yamada; Miyako Ohtake-Yamanaka; Yuko Okazaki; Tetsuji Sawada; Kazuhiko Yamamoto
Journal:  Biochem Biophys Res Commun       Date:  2005-07-29       Impact factor: 3.575

3.  Citrullination in extra-articular manifestations of rheumatoid arthritis.

Authors:  T Bongartz; T Cantaert; S R Atkins; P Harle; J L Myers; C Turesson; J H Ryu; D Baeten; E L Matteson
Journal:  Rheumatology (Oxford)       Date:  2006-06-16       Impact factor: 7.580

4.  MS analysis of rheumatoid arthritic synovial tissue identifies specific citrullination sites on fibrinogen.

Authors:  Monika Hermansson; Konstantin Artemenko; Elena Ossipova; Hanna Eriksson; Johan Lengqvist; Dimitrios Makrygiannakis; Anca I Catrina; Anthony P Nicholas; Lars Klareskog; Mikhail Savitski; Roman A Zubarev; Per-Johan Jakobsson
Journal:  Proteomics Clin Appl       Date:  2010-01-25       Impact factor: 3.494

5.  Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors.

Authors:  Xiaotian Chang; Jinxiang Han
Journal:  Mol Carcinog       Date:  2006-03       Impact factor: 4.784

6.  The presence of citrullinated proteins is not specific for rheumatoid synovial tissue.

Authors:  Erik R Vossenaar; Tom J M Smeets; Maarten C Kraan; Jos M Raats; Walther J van Venrooij; Paul P Tak
Journal:  Arthritis Rheum       Date:  2004-11

7.  Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule.

Authors:  Jonathan A Hill; Scott Southwood; Alessandro Sette; Anthony M Jevnikar; David A Bell; Ewa Cairns
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

8.  Human PAD4 regulates histone arginine methylation levels via demethylimination.

Authors:  Yanming Wang; Joanna Wysocka; Joyce Sayegh; Young-Ho Lee; Julie R Perlin; Lauriebeth Leonelli; Lakshmi S Sonbuchner; Charles H McDonald; Richard G Cook; Yali Dou; Robert G Roeder; Steven Clarke; Michael R Stallcup; C David Allis; Scott A Coonrod
Journal:  Science       Date:  2004-09-02       Impact factor: 47.728

9.  Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages.

Authors:  E R Vossenaar; T R D Radstake; A van der Heijden; M A M van Mansum; C Dieteren; D-J de Rooij; P Barrera; A J W Zendman; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

10.  Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease.

Authors:  Jon T Giles; Erika Darrah; Sonye Danoff; Cheilonda Johnson; Felipe Andrade; Antony Rosen; Joan M Bathon
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

View more
  2 in total

1.  Rheumatoid arthritis antigens homocitrulline and citrulline are generated by local myeloperoxidase and peptidyl arginine deiminases 2, 3 and 4 in rheumatoid nodule and synovial tissue.

Authors:  Sanna Turunen; Johanna Huhtakangas; Tomi Nousiainen; Maarit Valkealahti; Jukka Melkko; Juha Risteli; Petri Lehenkari
Journal:  Arthritis Res Ther       Date:  2016-10-20       Impact factor: 5.156

2.  PADI2 Polymorphisms Are Significantly Associated With Rheumatoid Arthritis, Autoantibodies Serologic Status and Joint Damage in Women from Southern Mexico.

Authors:  Iris Paola Guzmán-Guzmán; Claudia Isabel Ramírez-Vélez; Ramcés Falfán-Valencia; José Eduardo Navarro-Zarza; Ilse Adriana Gutiérrez-Pérez; Oscar Zaragoza-García; Mónica Ramírez; Natividad Castro-Alarcón; Isela Parra-Rojas
Journal:  Front Immunol       Date:  2021-08-04       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.